or Try an Advanced Search...

    Stage Pharmaceutical Stocks List

    Symbol Grade Name % Change
    CRNX B Crinetics Pharmaceuticals, Inc. 0.00
    CRMD B CorMedix Inc 0.00
    ITRM C Iterum Therapeutics plc 0.00
    SVRA C Savara, Inc. 0.00
    HRMY C Harmony Biosciences Holdings, Inc. 0.00
    KALV C KalVista Pharmaceuticals, Inc. 0.00
    PSTV C Plus Therapeutics, Inc. 0.00
    RPHM D Reneo Pharmaceuticals, Inc. 0.00
    KPTI F Karyopharm Therapeutics Inc. 0.00
    MBRX F Moleculin Biotech, Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Pharmaceutical Cancer Disease Medicine Blastoma Chemotherapy Clinical Medicine Glioblastoma Oncology Organ Systems Transcription Factors Acromegaly Acute Myeloid Leukemia Angioedema Antibody Drug Conjugate Antineoplastic Drugs Breast And Ovarian Cancer C1 Inhibitor CRM Carboxylic Acids

    Related ETFs - A few ETFs which own one or more of the above listed Stage Pharmaceutical stocks.

    Symbol Grade Name Weight
    MNTL D Tema Neuroscience and Mental Health ETF 3.18
    SBIO C ALPS Medical Breakthroughs ETF 2.8
    BBP C BioShares Biotechnology Products Fund 1.86
    JSML B Janus Small Cap Growth Alpha ETF 1.69
    PTH D Invesco DWA Healthcare Momentum ETF 1.44
    View all Stage Pharmaceutical ETFs...
    Compare ETFs
    Compare BBP to PTH Compare MNTL to JSML Compare MNTL to PTH

        Stage Pharmaceutical Stocks Recent News

        Date Stock Title
        May 8 CRNX Crinetics Pharmaceuticals Q1 2024 Earnings Preview
        May 8 PSTV Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
        May 8 KPTI Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
        May 8 KPTI Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
        May 8 CRNX Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
        May 8 KPTI Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript
        May 8 KPTI Karyopharm announces significant refinancing transactions
        May 8 KPTI Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed Review
        May 8 MBRX Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
        May 8 KPTI Karyopharm Therapeutics GAAP EPS of -$0.32 beats by $0.03, revenue of $33.13M misses by $1.34M
        May 8 KPTI Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
        May 8 KPTI Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
        May 7 SVRA Savara to Present at the Citizens JMP Life Sciences Conference
        May 7 KPTI Karyopharm Therapeutics Q1 2024 Earnings Preview
        May 7 MBRX Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
        May 7 RPHM Reneo Pharmaceuticals GAAP EPS of -$0.25
        May 7 RPHM Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
        May 6 PSTV Plus Therapeutics looks to raise $18 million through private placement
        May 6 PSTV Plus Therapeutics Announces Private Placement Financing of up to $18 Million
        May 4 HRMY Results: Harmony Biosciences Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Pharmaceutical Cancer Disease Medicine Blastoma Chemotherapy Clinical Medicine Glioblastoma Oncology Organ Systems Transcription Factors Acromegaly Acute Myeloid Leukemia Angioedema Antibody Drug Conjugate Antineoplastic Drugs Breast And Ovarian Cancer C1 Inhibitor CRM Carboxylic Acids
        Stage Pharmaceutical

        Stage Pharmaceutical is a biopharmaceutical company focused on developing innovative treatments for rare and neglected diseases. The company is developing a portfolio of novel therapies for rare and neglected diseases, including rare genetic disorders, rare cancers, and rare infectious diseases. Stage Pharmaceutical is committed to developing treatments that are safe, effective, and affordable for patients.

        Browse All Tags